IGF-1 LR3 typical research dosing
Across the available literature, IGF-1 LR3 is most commonly administered at 20–100 mcg per dose, 1 time(s) per day, via subcutaneous injection. Research protocols report doses of 20–100 mcg subcutaneously or intramuscularly once daily, typically post-exercise in muscle-focused studies. Short cycles (4 weeks on, 4 weeks off) are common due to concerns about receptor desensitization.
IGF-1 LR3 unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 1 mg IGF-1 LR3 vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 20 mcg | 60 mcg | 100 mcg |
|---|---|---|---|---|
| 1 mL | 1000 mcg/mL | 2.0 units | 6.0 units | 10.0 units |
| 2 mL | 500 mcg/mL | 4.0 units | 12.0 units | 20.0 units |
| 3 mL | 333 mcg/mL | 6.0 units | 18.0 units | 30.0 units |
| 5 mL | 200 mcg/mL | 10.0 units | 30.0 units | 50.0 units |
IGF-1 LR3 cycle length
Most reported IGF-1 LR3 protocols run 4 weeks on, then 4 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
IGF-1 LR3 half-life and timing
IGF-1 LR3 has a half-life of approximately 25 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.